LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies, cancer vaccines, and adoptive cell
therapies1 invites investors and the general public to
attend its Annual Meeting of Stockholders to begin at 5:00 p.m. ET today, Wednesday, June 20, 2018. The meeting is being held at the
Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for
attendees starts at 4:30 p.m. ET.
Webcast Information
A live webcast will be accessible from the Company's website at
http://investor.agenusbio.com/presentation-webcasts. The archived
replay will be available on the Agenus website for at least 60 days
following the meeting.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For more information,
please visit www.agenusbio.com; information that may be important
to investors will be routinely posted on our website.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-webcast-annual-meeting-of-stockholders-300669205.html
SOURCE Agenus Inc.